MedTrace Logo

Intermittent Neurogenic Claudication Treatment With APERIUS®

NCT00887744 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 162

Last updated 2016-01-28

Study results available
· View outcomes & findings →

Summary

The primary purpose of the study is to measure the change in severity of symptoms and ability to function in every day activities in patients suffering from degenerative lumbar spinal stenosis after treatment with the Aperius® device.

Conditions

  • Spinal Stenosis

Interventions

DEVICE

Aperius® Percutaneous Interspinous Spacer

Implantation of the Aperius® device

Sponsors & Collaborators

  • Medtronic Spinal and Biologics

    lead INDUSTRY

Principal Investigators

  • E. Wuelfert, Pharm. · Medtronic Spinal & Biologics

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2009-05-31
Completion
2010-03-31

Countries

  • Belgium
  • Germany
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00887744 on ClinicalTrials.gov